Inloggad som:
Majestec-3
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
Majestec-3
En studie som jämför teclistamab i kombination med daratumumab (Tec-Dara) med daratumumab, pomalidomid och dexametason (DPd) eller daratumumab, bortezomib och dexametason (DVd) hos patienter med återfall eller refraktärt multipelt myelom (MajesTEC-3)
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma
Skånes universitetssjukhus / Hematologisk vård
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants with Relapsed or Refractory Multiple Myeloma
Mer information om studien för vårdgivare
1. ≥18 years of age.
2. Documented multiple myeloma as defined by the criteria below: a. Multiple myeloma diagnosis according to the IMWG diagnostic criteria (for more info see link)
Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients (refer to the teclistamab Investigator’s Brochure and appropriate package inserts), including: a. A participant is not eligible to receive DPd as control therapy (see link)
Behandling
Fas 3
Kurativ
Ej tillämpbar
Företag
Studien ändrades senast: (2025-09-30)